WGI-0301 for Solid Tumors

Recruiting at3 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Recruiting

Sponsor: Zhejiang Haichang Biotech Co., Ltd.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a new medicine called WGI-0301 to find the best dose for treating solid tumors. It aims to see how safe and tolerable the medicine is for patients with these tumors. Researchers will also study how the body absorbs and reacts to the medicine.

Research Team

Eligibility Criteria

Adults (18+) with advanced solid tumors that have worsened after treatment or are untreatable, who can understand and consent to the study. They must be in fairly good health overall, not pregnant, willing to use contraception, and expected to live at least 12 weeks. People with certain other medical conditions or treatments are excluded.

Inclusion Criteria

Capable of understanding the written informed consent, provides signed, dated, and witnessed written informed consent, and agrees to comply with the study protocol

My cancer has returned or worsened after treatment and cannot be cured with surgery or other therapies.

My advanced cancer did not respond to standard treatments.

Exclusion Criteria

I am currently taking medication that strongly affects drug metabolism.

My blood pressure is very high or very low, and my heart rate is too fast or too slow.

I have not had any cancer except for specific skin, prostate, melanoma, or cervical cancers treated over 5 years ago.

Treatment Details

Interventions

• WGI-0301 (Other)

Trial Overview The trial is testing WGI-0301's safety and optimal dosing for treating solid tumors. It involves studying how the body absorbs it (pharmacokinetics) and its effects on the body (pharmacodynamics).

Participant Groups

Group I: WGI-0301 Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

Zhejiang Haichang Biotech Co., Ltd.

Lead Sponsor

Trials

2

Recruited

80+